| Biomarker ID | 886 |
| PMID | 22371711 |
| Year | 2012 |
| Biomarker | miR143; miR145; miR221; |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially expressed (Median Fold Change): [miR143 (MFD: -1.78 fold); miR145 (MFD: -4.77 fold); miR221 (MFD: -1.52 fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miRNA-143):- DNA-binding transcription factor activity; Senescence and Autophagy in Cancer; Glioma; Focal adhesion; Melanoma Pathways Include(miR-145):- positive regulation of transcription by RNA polymerase II; DNA-binding transcription activator activity, RNA polymerase II-specific; positive regulation of gene expression; Pancreatic adenocarcinoma pathway; positive regulation of cell population proliferation Pathways Include(miR-221):-homophilic cell adhesion via plasma membrane adhesion molecules; transcription by RNA polymerase II; regulation of transcription by RNA polymerase II; DNA binding; synapse |
| Experiment | Metastatic Vs Primary |
| Type of Biomarker | Diagnostic |
| Cohort | 131 primary prostate cancer, 29 normal adjacent, and 19 metastatic specimens were downloaded from GEO Omnibus at GSE21034. (Dataset was: Memorial Sloan–Kettering Cancer CenterProstate Oncogenome Project) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.04 |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | miR143, miR145, miR221 |